NEWS: Padres Pedal the Cause is coming back to Petco Park on April 9, 2022. Early Bird fundraising commitment promotion now through February 4! Register Now
When we are 100% committed and 100% united, our mission becomes 1000% more achievable.
JOIN US
Join Curebound in the fight against cancer and help accelerate research into life-saving cures.
WAYS
TO GIVE
2. BECOME A CORPORATE PARTNER
Corporate collaboration and cooperation is integral to our mission at Curebound. We look forward to connecting with you on a partnership opportunity with your organization.
EVENTS
PARTNERS
AND SPONSORS
Curebound is proud to partner with these corporate leaders who share a commitment to creating a world without cancer. Together, we can go further, move faster and do more to accelerate cures for patients today.
NEWS AND UPDATES
Padres Pedal the Cause Kicks Off Childhood Cancer Month by Presenting Rady Children’s Hospital with $229,000
Padres Pedal the Cause (PPTC), a local non-profit funding collaborative cancer research in San Diego, hosted their annual fundraising event virtually in May 2021, raising an astounding $1.5M.
Curebound Launches and Commits to Invest $100 Million into Cancer Research
On November 30th, the formation of a newly launched organization, Curebound, was announced at a Scientific Advisory Board meeting at Farmer & the Seahorse in La Jolla. The event brought together experts from San Diego’s top cancer research institutions alongside prominent leaders from the life science, venture capital and biotech industries with the goal of finding a cure for cancer in our lifetime.
Curebound Donates More than $476,000 for Cancer Immunotherapy Clinical Trial
La Jolla-based nonprofit Curebound made a $476,450 donation to UC San Diego and La Jolla Institute for Immunology to fund a cancer immunotherapy clinical trial that the university and the institute started in partnership with the Immunotherapy Foundation.
Curebound
9191 Towne Centre Dr. Suite 310
San Diego, CA 92122
Sign up to receive more information and updates from Curebound.
